8-K/AOther EventsExhibits & Filings

PFIZER INC 8-K/A Report, Corporate Update (Nov 14, 2016)

Filed November 14, 2016For Securities:PFE

Summary

Pfizer Inc. (PFE) filed an amendment to a previous 8-K filing, primarily to correct a typographical error in a press release. The original filing on November 14, 2016, announced the commencement of a tender offer for its 6.200% Senior Notes due March 15, 2019. This amendment clarifies that the press release contained an incorrect website address for accessing offer documents from Global Bondholder Services Corporation. For investors holding these specific notes, the key takeaway is the confirmation of a tender offer, indicating Pfizer's intention to repurchase these outstanding debt securities. While the amendment itself does not alter the terms or existence of the tender offer, it rectifies a minor administrative detail in the public announcement. Investors should refer to the actual tender offer documents for complete details on pricing, deadlines, and participation.

Key Highlights

  • 1Pfizer Inc. (PFE) filed an 8-K/A (Amendment) on November 14, 2016.
  • 2The amendment corrects a typographical error in a press release previously filed with the SEC.
  • 3The error involved an incorrect website address for downloading tender offer documents.
  • 4The original Form 8-K announced the commencement of a tender offer for Pfizer's 6.200% Senior Notes due March 15, 2019.
  • 5The tender offer is for cash and seeks to purchase 'any and all' outstanding notes.
  • 6No other changes were made to the original Form 8-K filing.
  • 7The press release, as corrected, is attached as Exhibit 99.1.

Frequently Asked Questions

The primary purpose of this 8-K/A filing is to correct a typographical error in the website address provided in a press release that announced Pfizer's tender offer for its 6.200% Senior Notes due March 15, 2019. No other information in the original filing has been changed.

No, this amendment does not change the terms or conditions of the tender offer itself. It only rectifies a minor administrative error regarding the website where tender offer documents can be accessed.

Pfizer is commencing a tender offer to purchase for cash any and all of its outstanding 6.200% Senior Notes that are due to mature on March 15, 2019.

Investors should refer to the official tender offer documents. The press release announcing the offer, which is incorporated by reference in this filing, will direct holders to the website of Global Bondholder Services Corporation for the offer to purchase and related documents.